For research use only. Not for therapeutic Use.
NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC50 value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research[1][2].
NNC 55-0396 (0.1-1000 μM) shows no inhibition to the HVA Ca2+ currents in INS-1 cells[1].
NNC 55-0396 (1-100 μM) blocks more than 50% of the T-type Ca2+ current at 8 μM in HEK 293/α1G cells[1].
NNC 55-0396 blocks T-type Ca2+ current with an IC50 value of 6.8 μM[1].
NNC 55-0396 (20 mg/kg; i.p. once) suppresses tremor in GABAA subunit α1-null mice and harmaline mouse models[1].
Catalog Number | I003310 |
CAS Number | 357400-13-6 |
Synonyms | [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] cyclopropanecarboxylate;dihydrochloride |
Molecular Formula | C30H40Cl2FN3O2 |
Purity | ≥95% |
InChI | InChI=1S/C30H38FN3O2.2ClH/c1-20(2)28-24-13-12-23(31)19-22(24)14-15-30(28,36-29(35)21-10-11-21)16-18-34(3)17-6-9-27-32-25-7-4-5-8-26(25)33-27;;/h4-5,7-8,12-13,19-21,28H,6,9-11,14-18H2,1-3H3,(H,32,33);2*1H/t28-,30-;;/m0../s1 |
InChIKey | BCCQNBXHUMKLFW-HNQRYHMESA-N |
SMILES | CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)C5CC5)C=C(C=C2)F.Cl.Cl |
Reference | [1]. Arnulfo Quesadaa, Peter H. Bui, Gregg E. Homanics,et al. Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. European Journal of Pharmacology. 2011,659 (1): 30-36. [2]. Hideto Miwa, Jinsoo Koh, Yoshinori Kajimoto, et al. Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats. Pharmacology Biochemistry and Behavior. 2011,97(4): 656-659. [3]. Huang L, Keyser BM, Tagmose TM, et al. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther. 2004 Apr;309(1):193-9. |